Exploring solutions to optimise viral research and COVID-19 vaccine development
Date: 23 March 2021 - 25 March 2021
Time: All Day
Website: bit.ly/3bCmwez
The coronavirus (COVID-19) pandemic has led to a worldwide effort in the scientific community to develop new tests, vaccines and treatments for this disease as quickly as possible, as well as to quickly understand more about the basic biology of SARS-CoV-2 and how it interacts with the human body. It has also led to an upsurge of interest in virology research more generally, across a wide range of disciplines.
In this webinar series, over two days, experts from Beckman Coulter Life Sciences, Cytiva, IDT, Leica Microsystems, Molecular Devices, Pall Corporation, Phenomenex and SCIEX will introduce methods and techniques to accelerate your virology research and viral vector vaccine production.
You will learn about:
- Accelerating study of viral infection and therapeutics with microplate-based detection and high-throughput screening
- Research automation solutions during COVID-19 for viral extraction/detection and drug discovery/repurposing
- Mass spectrometry and capillary electrophoresis applications for virology research
- Profiling of SARS-CoV-2 viral peptides by micro and nano LC coupled with MS HPLC and LC-MS workflows to characterize COVID related vaccine research & development
- Exploring the structure and life cycle of viruses: The virologist’s toolbox for electron microscopy specimen preparation
- Achieving optimal results in analytical chemistry sample preparation and mobile phase filtration
- HPLC and LC-MS workflows to characterize COVID related vaccine development
- Adenovirus vector vaccine production for pandemic use
- Viral RNA isolation and concentration, sterile filtration of media kits and reagents, and waste water surveillance
- NGS RNA virus surveillance methods
Click here to view the full agenda
Related topics
Biologics, Drug Discovery, High-Performance Liquid Chromatography (HPLC), High-Throughput Screening (HTS), Mass Spectrometry, Microscopy, Next-Generation Sequencing (NGS), RNAs, Therapeutics, Vaccine
Related organisations
Molecular Devices